secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001193125-22-144970
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q1 net loss $57.6M; RAS(ON) inhibitors advancing toward clinic
--------------------------------------------------------------------------------

- Net loss $57.6M vs $37.2M YoY; revenue $7.6M from Sanofi collaboration (down from $10.2M).
- Cash and securities $518.8M at Mar 31, 2022, down from $577.1M at Dec 31, 2021.
- FY 2022 net loss guidance reaffirmed at $260M-290M, including $35M-40M stock-based comp.
- IND submitted for RMC-6236 (RAS MULTI); first patient dosing mid-2022. RMC-6291 IND on track for H1 2022.
- RMC-4630 Phase 2 combo with sotorasib enrolling; enrollment completion expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522144970/0001193125-22-144970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522144970/d285264d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-144970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer